

In the Specification:

Pursuant to 37 C.F.R. § 1.121(b)(3), please replace the specification with the attached substitute specification which is in permanent ink as required by 37 C.F.R. §1.52(a). No marked-up copy of the substitute specification is attached as no previous amendments were made.

In the Title:

Please amend the Title to read:

a. Method for Treating Autoimmune and Alloimmune Diseases

In the Specification:

Please insert the following paragraph on Page 1, line 2:

CROSS REFERENCE TO RELATED APPLICATIONS

a2 This application claims the benefit of United States Provisional Application Serial Number 60/127,621, filed on April 1, 1999.

In the Claims: ✓

a3 6. (amended) The method of claim 5, wherein said recombinant TNF receptor is selected from the group consisting of recombinant human TNF receptor p55 Fc fusion protein (p55 TNFR:Fc) and recombinant human TNF receptor p75 Fc fusion protein (p75 TNFR:Fc).